Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

How to improve drug development for functional disorders.

Jan Tack1, Maura Corsetti

  • 1Division of Gastroenterology, Department of Internal Medicine, University Hospital Gasthuisberg, Herestraat 49, Leuven B-3000, Belgium. jan.tack@med.kuleuven.ac.be

Best Practice & Research. Clinical Gastroenterology
|August 25, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Worldwide prevalence and burden of gastroparesis-like symptoms as defined by the United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis.

United European gastroenterology journal·2022
Same author

Editorial: refractory reflux sensitivity-A place for baclofen? Authors' reply.

Alimentary pharmacology & therapeutics·2022
Same author

Exploring the pathophysiology of LARS after low anterior resection for rectal cancer with high-resolution colon manometry.

Neurogastroenterology and motility·2022
Same author

Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility.

United European gastroenterology journal·2022
Same author

Clinical trial: a controlled trial of baclofen add-on therapy in PPI-refractory gastro-oesophageal reflux symptoms.

Alimentary pharmacology & therapeutics·2022
Same author

Zhizhu Kuanzhong Capsule in treating patients with functional dyspepsia postprandial distress syndrome: study protocol for a multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial.

Trials·2022
Same journal

Needle-based confocal laser endomicroscopy and artificial intelligence in pancreatic cystic lesions: Insights and clinical advances.

Best practice & research. Clinical gastroenterology·2026
Same journal

Evidence-based approach to the diagnosis, management and surveillance of pancreatic cystic lesions: from the guidelines to the clinical practice.

Best practice & research. Clinical gastroenterology·2026
Same journal

Pancreatic cystic lesions in hereditary syndromes: Diagnostic role of endoscopic ultrasound.

Best practice & research. Clinical gastroenterology·2026
Same journal

Predictive risk models for the diagnosis and cancer progression of pancreatic cysts.

Best practice & research. Clinical gastroenterology·2026
Same journal

Preface.

Best practice & research. Clinical gastroenterology·2026
Same journal

Endoscopic ultrasound-guided treatment of pancreatic lesions.

Best practice & research. Clinical gastroenterology·2026
See all related articles

Developing new drugs for functional bowel disorders is challenging due to patient heterogeneity and poor understanding of disease mechanisms. More mechanistic studies are needed to improve drug development success rates.

Area of Science:

  • Gastroenterology
  • Pharmacology
  • Clinical Trials

Background:

  • Functional bowel disorders (FBDs) present significant challenges for pharmacotherapeutic development.
  • Despite numerous studies, successful drug development programs for FBDs remain limited.
  • Key difficulties include patient heterogeneity, poorly understood pathophysiology, and inadequate mechanistic studies.

Purpose of the Study:

  • To highlight the challenges in developing pharmacotherapeutic approaches for functional bowel disorders.
  • To emphasize the need for improved understanding of FBD pathophysiology.
  • To suggest future directions for more effective drug development.

Main Methods:

  • This study is a review and analysis of existing literature on drug development for functional bowel disorders.

Related Experiment Videos

  • It critically examines the limitations of current research methodologies.
  • It discusses the impact of patient heterogeneity on clinical trial outcomes.

    • Main Results:

    • Drug development for FBDs is hampered by the diverse nature of these conditions.
    • Current mechanistic studies often fail to predict clinical outcomes or optimal dosing.
    • Lack of patient stratification based on specific pathophysiological mechanisms limits drug efficacy.

    Conclusions:

    • Further mechanistic studies are crucial to advance our understanding of FBD pathophysiology.
    • Development of non-invasive diagnostic tests to identify mechanisms is recommended.
    • Refining symptom assessment and implementing short-term therapeutic trials are vital for future drug development.